Jincheng Pharmaceutical Unit Gets China License for Good Manufacturing Practice, Production
Shandong Jincheng Pharmaceutical Group (SHE:300233) subsidiary Beijing Jincheng Taier Pharmaceutical obtained a good manufacturing practice compliance certification and production license from the Beijing Drug Administration for its nabumetone dispersible tablets.
Nabumetone is indicated for pain due to rheumatoid arthritis and osteoarthritis.
Price (RMB): ¥11.27, Change: ¥+0.080, Percent Change: +0.71%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.